Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that it has received approval from the National Medical Products Administration (NMPA) to initiate a Phase II clinical study for its Bcl-2 inhibitor FCN-338 in combination with the BTK inhibitor FCN-647, targeting chronic lymphocytic leukemia/small lymphocytic lymphoma.
FCN-338 is currently being evaluated in Phase I clinical trials for malignant hematological tumors and recurrent or refractory B-cell lymphoma in both China and the U.S. The drug is also undergoing a Phase II study in China for malignant hematological diseases of the medullary system, in combination with azacitidine or chemotherapy. Additionally, it received clearance for a Phase II study in systemic light chain amyloidosis with dexamethasone earlier this year. Meanwhile, a Phase I clinical trial for FCN-647 is in progress in China, focusing on recurrent or refractory B-cell lymphoma.- Flcube.com
